Wu, S., Ho, C., Yang, J. C., Yu, S., Lin, Y., Lin, S., . . . Shih, J. Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. Wiley.
Chicago Style (17th ed.) CitationWu, Shang‐Gin, et al. Atezolizumab, Bevacizumab, Pemetrexed and Platinum for EGFR‐mutant NSCLC Patients After EGFR TKI Failure: A Phase II Study with Immune Cell Profile Analysis. Wiley.
MLA (9th ed.) CitationWu, Shang‐Gin, et al. Atezolizumab, Bevacizumab, Pemetrexed and Platinum for EGFR‐mutant NSCLC Patients After EGFR TKI Failure: A Phase II Study with Immune Cell Profile Analysis. Wiley.
Warning: These citations may not always be 100% accurate.